Trial Profile
International Real-World Study Assessing Impact Of The Burden Of Systemic Juvenile Idiopathic Arthritis (SJIA) On Patients And Caregivers.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2017
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Canakinumab (Primary) ; Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 12 Oct 2017 Results (n-61) presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 25 Jan 2017 New trial record